Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation
In this first target trial emulation of metformin and exceptional longevity, we found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes. Because this comparison was not made to placebo in a randomized controlled trial and given the observational design with potential for residual confounding, causality cannot be inferred.
Authors
- Karen Johnson (ORCID: https://orcid.org/0000-0002-3493-4077)
- Aladdin H. Shadyab (ORCID: https://orcid.org/0000-0002-9693-0522)
- Bernhard Haring (ORCID: https://orcid.org/0000-0001-6109-431X)
- Andrew Odegaard (ORCID: https://orcid.org/0000-0002-8357-8398)
- Mark A. Espeland (ORCID: https://orcid.org/0000-0002-3711-1949)
- Andrea Z. LaCroix (ORCID: https://orcid.org/0000-0002-9532-976X)
- Bowei Zhang (ORCID: https://orcid.org/0009-0000-9686-0897)
- Zhao Chen (ORCID: https://orcid.org/0000-0002-5659-0447)
- JoAnn E. Manson (ORCID: https://orcid.org/0000-0002-9426-7595)
Institutions
- Brigham and Women's Hospital (US)
- Albert Einstein College of Medicine (US)
- Harvard University (US)
- University of Arizona (US)
- University of Tennessee Health Science Center (US)
- University of California, Irvine (US)
- Arizona Science Center (US)
- University of California San Diego (US)
- Human Longevity (United States) (US)
- Wake Forest University (US)
- Saarland University (DE)
Publication Details
- Journal
- The Journals of Gerontology Series A
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1093/gerona/glaf095
- Citations
- 2
- Primary Topic
- Dietary Effects on Health
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- U.S. Department of Health and Human Services
- National Institutes of Health
- National Heart, Lung, and Blood Institute